



VGX Pharmaceuticals Announces Reorganization of its Manufacturing Assets

Blue Bell, PA – June 3, 2008 -

VGX Pharmaceuticals (VGX) announced today that the Company has consolidated all of its manufacturing assets under the management of its publicly-traded, Korea-based affiliate, VGX International, Inc. The primary asset, a DNA plasmid manufacturing facility in The Woodlands, TX, currently operates a 500-liter scale bioreactor under cGMP (current Good Manufacturing Practices) guidelines.

The reorganization focuses the strategic objectives of both firms and allows the Company to devote its resources exclusively to research and clinical development of novel product candidates. It also enables VGX International to provide efficient and cost-effective manufacturing of DNA-based products for clinical supplies, from Phase I to Phase III, as well as commercial products for VGX and other contract clients. In October 2007, VGX International initiated a major project to construct and operate a large-scale (3000-liter) cGMP, DNA plasmid manufacturing facility in Korea – the first of its kind in Asia.

Products manufactured at the state-of-the-art Texas facility have entered human clinical trials. In less than one year, the facility has manufactured all of the Company's Phase I product supplies for its current DNA-based clinical candidates including: VGX-3100, a therapeutic vaccine for cervical cancer; VGX-3200, a therapeutic based on human growth hormone releasing hormone for cancer-related cachexia; and VGX-3400, a novel DNA vaccine for avian influenza. In addition, the facility has manufactured clinical product supplies under contract for leading companies and non-profit organizations.

"The reorganization allows VGX Pharmaceuticals to focus on maintaining its rapid pace of developing novel product candidates for infectious diseases and cancer," said Dr. J. Joseph Kim, President and CEO. "It will also enable VGX International to become the world-class, "go-to" manufacturer of DNA-based products at any stage of development from 10-liter scale to 3000-liter scale. We believe the streamlined operations will significantly benefit the Company and VGX International's other contract manufacturing clients as they advance their product candidates."

In November 2005, the Company acquired a controlling interest of a publicly traded pharmaceutical company, which was subsequently renamed VGX International Inc. (Korean Stock Exchange: Stock Ticker No. 011000), to expand its overseas manufacturing and marketing capabilities. Since then, VGX International has become a leading entity in the manufacture of biopharmaceutical products in Asia.

Cautionary Factors That May Affect Future Results - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies

such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, PENNVAX™-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, the Company has filed INDs for VGX-3100, a DNA therapeutic vaccine for cervical cancer; VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia; and VGX-3400, a DNA preventative vaccine for avian influenza. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon™ DNA-based product candidates, the CELLECTRA® delivery device, and efficient cGMP plasmid manufacturing facilities. The cGMP facilities are used for VGX's own product supplies and for contract manufacturing. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from bench-to-IND filing, within 1 year. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

About VGX International

VGX International, a publicly-traded global biopharmaceutical company listed on Korean Stock Exchange. VGX International is headquartered in Seoul, Korea. The Company is dedicated to developing revolutionary new drug candidates for the treatment of cancer and inflammatory diseases, providing the most advanced cGMP solutions for better facilities, and supplying high-end biopharmaceutical products to global clients. The Company's clinical development programs include VGX-1027 for type 1 diabetes and VGX-100 for gastric cancer, which are both currently in pre-clinical stages. The Company provides cGMP manufacturing solutions to other pharmaceutical companies in Asia for new construction of GMP facilities and its related fields. The Company also provides contract manufacturing services dedicated to supplying biopharmaceutical products to global institutions and companies working on DNA therapies. More information about VGX International can be found at www.vgxi.com.

Company Contact:

Kevin W. Rassas
Senior Vice-President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com